Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab.
R A Manneh KoppJ M Sepúlveda-SánchezY RuanoO ToldosA Pérez NúñezD CanteroA HilarioA RamosG de VelascoP Sánchez-GómezAurelio Hernández-LaínPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2019)
Unfortunately, in this histopathological, molecular, immunohistochemical and neuroradiological study we did not find any predictive biomarker of response or survival benefit for Bevacizumab in glioblastoma.